Strategy Optimization and Clinical Analyze of Multiple Nucleotide Polymorphism Analysis in the Chimerism Detection after Allogeneic Hematopoietic Stem Cell Transplantation.
10.19746/j.cnki.issn.1009-2137.2022.03.040
- Author:
Zhe ZOU
1
;
Rui SUN
1
;
Yang-Wei LI
1
;
Zhen GUO
1
;
Rui-Hua FAN
1
;
Xiao-Dong LYU
2
Author Information
1. Central Laboratory, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China.
2. Central Laboratory, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China,E-mail：13523417973@163.com.
- Publication Type:Journal Article
- Keywords:
STR;
allogeneic hematopoietic stem cell transplantation;
chimerism;
multiple nucleotide polymorphism
- MeSH:
Chimerism;
Hematopoietic Stem Cell Transplantation;
Humans;
Nucleotides;
Reproducibility of Results;
Retrospective Studies;
Transplantation Chimera/genetics*;
Transplantation, Homologous
- From:
Journal of Experimental Hematology
2022;30(3):913-918
- CountryChina
- Language:Chinese
-
Abstract:
AbstractObjective: To investigate the sample selection, result correction and clinical application value of multi nucleotide polymorphism chimerism detection method based on Next-generation sequencing.
METHODS:The chimerism samples from November 2018 to June 2020 were collected, and Pearson correlation coefficient (r) was used to analyze the consistency of bone marrow and peripheral blood results detected by MNPseq; according to the different information integrity before transplantation, the calibration model was constructed to analyze the correction value of the micro chimerism results in each model; the clinical results were retrospectively analyzed to verify the reliability and practicability of chimerism results correction and the clinical value of MNPseq method.
RESULTS:The results of bone marrow and peripheral blood chimerism detected by MNPseq method were consistent with each other and showed significant correlation (r=0.985, P<0.01). The three groups of calibration models were constructed according to different pre-transplant information. For the no donor and pre-transplant patients information group, the correction value was 1%; while for the group with pre-transplant patients and without donor information, 0.61% of the chimerism rate and 13 heterotopic points were used as the correction value; 0.26% of the chimerism rate and 21.57% of the heterotopic points were used as the correction value for the group with pre-transplantation patients and donor information. After correction, the number of the patients with incomplete chimerism decreased from 276 (74.19%) to 141 (37.91%) (P<0.01). Among 18 (18/141, 12.77%) patients with incomplete chimerism, the results of MNPseq in the patients were 25-39 days earlier than those in STR and flow MRD, and the result showed statistical significance.
CONCLUSION:MNPseq method can be used to monitor chimerism with peripheral blood instead of bone marrow samples, and the results can be corrected to detect the changes of graft status in vivo in a more timely manner.
